Back

Sacubitril/valsartan initiation among renin-angiotensin aldosterone system inhibitor-naive heart failure patients with reduced ejection fraction

26 May 2018 (08:54 - 09:00)
Organised by:
Congress Presentation Part of: Heart failure prognosis and the options to improve Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2018

About the speaker

Photo
Doctor April Mohanty

University of Utah, Salt Lake City (United States of America)

14 More presentations in this session

Presentation thumbnail
The impact of anthropometric measures of obesity on heart failure outcomes in Asia
Doctor C. Chandramouli (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
S2PLIT Score: a simple risk score predicting post-discharge 1-year mortality in patients with acutely decompensated heart failure
Mr J. Borovac (Split, HR)
Abstract Slides Video
Presentation thumbnail
Increased all-cause mortality in newly diagnosed patients with heart failure between 2006 and 2012: a retrospective, population-based study in Sweden
Professor K. Lindmark (Umea, SE)
Presentation thumbnail
One year follow-up of heart failure patients: role of the new tnm-like classification
Doctor M. Pucci (Rome, IT)
Abstract Slides Video
Presentation thumbnail
High-dose loop diuretics are associated with adverse clinical outcomes in outpatients with chronic heart failure and mid-range and preserved ejection fraction: observations from the ESC Heart Failure
Doctor C. Kapelios (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure prognosis and the options to improve

The Event

Event poster

Heart Failure 2018

26 May 2018 08:54 CET
You may be interested in
thumbnail
Congress Presentation
Treatment trajectory of Sacubitril/Valsartan initiation among >50,000 older adults with heart failure with reduced ejection fraction in the United States
21 May 2023
thumbnail
Congress Session
New treatments on the horizon
20 May 2025
thumbnail
Congress Presentation
Early reverse remodelling assessed by myocardial work after sacubitril-valsartan therapy
3 September 2019
thumbnail
Congress Session
Neprilysin inhibition: news and nuggets
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources